Palo Alto, CA, United States of America

Daniel J Cua

USPTO Granted Patents = 10 

 

Average Co-Inventor Count = 3.9

ph-index = 4

Forward Citations = 84(Granted Patents)


Location History:

  • Palo Alto, CA (US) (2011 - 2016)
  • Boulder Creek, CA (US) (2008 - 2022)

Company Filing History:


Years Active: 2008-2022

Loading Chart...
Loading Chart...
10 patents (USPTO):

Title: The Innovations of Daniel J Cua

Introduction

Daniel J Cua is a prominent inventor based in Palo Alto, California. He has made significant contributions to the field of biotechnology, holding a total of 10 patents. His work primarily focuses on the development of antibodies and methods for modulating interactions between various ligands.

Latest Patents

Among his latest patents is the invention related to the ILT3 ligand. This invention provides antibodies and antigen-binding fragments that bind ILT3, ILT3 ligand (i.e., PI16), or a complex between ILT3 and the ILT3 ligand. Additionally, it includes methods for determining whether ILT3 and the ILT3 ligand bind together or whether a substance agonizes or antagonizes such binding. Another notable patent is for the MDL-1 ligand, which provides methods for modulating interactions between MDL-1 and its binding partner, Gal9. This patent also includes methods to screen for modulators of the MDL-1/Gal9 interaction.

Career Highlights

Daniel has worked with several reputable companies throughout his career, including Schering Corporation and Merck Sharp & Dohme Corporation. His experience in these organizations has allowed him to develop and refine his innovative ideas in the biotechnology sector.

Collaborations

Some of his notable coworkers include Edward P Bowman and Shi-Juan Chen. Their collaborative efforts have contributed to the advancement of research and development in their respective fields.

Conclusion

Daniel J Cua's contributions to biotechnology through his patents and collaborations highlight his role as a significant inventor in the industry. His work continues to influence advancements in the understanding and application of ligands and antibodies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…